Yes (and no) The study of tamoxifen and Raloxifene (star) trial compared the effectiveness of these two drugs in the prevention of breast cancer and found them to be equally effective, with a 50% reduction in invasive breast cancer as compared to placebo. However, only tamoxifen reduced the rate of carcinoma in situ (dcis, lcis).
For invasive cancer. Evista (raloxifene) and tamoxifen were compared in the star trial. The results showed that Evista (raloxifene) was just as effective as reducing the risk of invasive cancer as tamoxifen with fewer side effects. There was no difference in the risk of developing dcis, ore ductal carcinoma in-situ.
I had breast cancer and developed severe osteoporosis whilst on arimidex/ooph, now on strontium ranelate. Is evista (raloxifene) a safer med or are they similar?
Evista (raloxifene) is safe. Evista is a good medicine to prevent osteoporosis. Since you already have osteoporisis, for you the best medicine would be one of the bisphosphonates (there are several to choose from). Examaples include zoledronic acid (zoedronate), Fosamax and boniva (ibandronate).
Possibly. Raloxifene/evista is similar to tamoxifen -both are serms. Evista (raloxifene) was developed for osteoporosis. It has been investigated & compared to tam for prevention but has not been studied for cancer treatment. Talk with you cancer doctors as to what the best hormonal therapy options for you may be (including minding bone effects).
Not usually. This is a drug like tamoxifen. It is used for risk prevention. It is also used in a condition called lobular cancer in situ, which is a non spreading kind of cancer. It has been used in some cases of breast cancer, but is not the drug of choice.
Only One Dose. The use of tamoxifen for chemoprevention is associated with a 50% reduction in breast cancer in those at high risk. Like any drug, there are side-effects and potential complications. Therefore, this decision is best made in consultation with a cancer specialist.
Yes. Tamoxifen is an antiestrogen that blocks the ability of breast cancer cells to use estrogen; therefore, it is only effective in hormone sensitive (estrogen receptor +) breast cancers. When taken for 5 years, tamoxifen has been shown to both stop the growth of cancer cells in breast cancer patients and to prevent the development of breast cancer in women that are at high risk.
Is Possible. Tamoxifen is used as a hormone therapy in the breast cancers that exhibit an estrogen hormone receptor. (er+ tumors).
Sometimes, Depending on type of cancer, especially hormone receptor status. But it really depends on specific circumstances whether this drug, or any drug, is appropriate drug for you. So you need to ask your doctor for specific advice.
Yes. Tamoxifen use may reduce the development of breast cancer in high-risk patients by about 50%. There are risks associated with tamoxifen, so the decision whether to take this medication is based upon an individual patient's risk:benefit analysis.
Yes - ER+ breast CA. The p-1 trial showed in high risk women tamoxifen decreased the risk of er+ tumors by 40-50% (no difference in er- tumors) over palcebo. The p-2 or star trial compared tamoxifen to raloxifene/evista and saw similar overall benefits with some slight variations. Recently, a new trial has shown 65% reduction benefit for the aromatase inhibitor Exemestane over placebo.
Recurrence. It prevents recurrence in women with estrogen receptor positive tumors.
And new primaries. Tamoxifen blocks estrogen and Progesterone receptors which when stimulated can cause remnant cancer cells to be stimulated to grow back and also can cause normal cells to be overstimulated to develop into new hormonally sensitive cancer. Statistically it reduces the chance of recurrence by 30% and reduces the chance of a second primary by 50%.
Secondary Prevention. Tamoxifen also can be used to prevent breast cancer in the other breast as well as "secondary prevention" of breast cancer in patients who are at higher than normal risk of developing breast cancer.
Is combined tamoxifen plus hormonal therapy better for breast cancer in pre or postmenopausal women?
Need to know. Er/pr receptor status on resected tumor, as if these are negative, no role for hormone therapy. Post orpre-menopausal er+ patients are treated with the effective, cheap, low adverse effect tamoxifen, a useful drug for more than 30 years. But ovarain function precluses use of anastrazome or the newer more expensive letrozole. These all work; toxiicty and cost vary.
Hormonal treatment. In general, tamoxifen is used for premenopausal women and aromatase inhibitors are used for postmenopausal women.
Estrogen supression. In general, aromatase inhibitor is only indicated for postmenopausal women ;not for premenopausal; while on the other hand, tamoxifen can be given either in pre or postmenopausal. Only thing is that tamoxifen can cause a little bit higher risk for complication -i.e. Risk for blood clots and risk for develping uterine cancer- when used in older population- age of -65 Y.O. Or above.